Exhibit 10.1  |
| AMENDMENT 2 |
| TO THE |
| COLLABORATIVE RESEARCH AGREEMENT |
| BETWEEN |
| GENERAL ELECTRIC COMPANY |
| AND |
| ENDRA LIFE SCIENCES INC. |
| This Amendment 2 to the Collaborative Research Agreement ("Amendment"), effective as of the last date of signing below ("Effective Date"), amends the TERM between General Electric ("GE") & ENDRA Life Sciences Inc. ("Endra"), which became effective as of April 22, 2016, as amended by that certain Amendment 1 to the Collaborative Research Agreement, dated April 21, 2017 ("Agreement"). |
| RECITALS |
| WHEREAS, the parties wish to amend the Agreement to provide for a revised TERM, which includes changes to the Agreement as set forth below; |
| THEREFORE, the parties hereby agree to the following amendment: |
1. Section 9.1 of Collaborative Research Agreement shall be deleted and restated as follows: This Agreement will remain in effect until January 22, 2020 unless terminated sooner or extended in writing signed by the parties in accordance with this Agreement. |
| 2. Capitalized terms not defined in this Amendment will have the meanings assigned in the Agreement. |
| 3. Except as explicitly modified, all terms, conditions and provisions of the Agreement shall continue in full force and effect. |
| 4. In the event of any inconsistency or conflict between the Agreement and this Amendment, the terms, conditions and provisions of this Amendment shall govern and control. |
| 5. This Amendment and the Agreement constitute the entire and exclusive agreement between the parties with respect to this subject matter. All previous discussions and agreements with respect to this subject matter are superseded by the Agreement and this Amendment. |
Acceptance of these terms is documented by the signature and date of the responsible parties in the space designated below.
GE Healthcare | ENDRA Life Sciences Inc. |
Signature: /s/ Brian McEathron | Signature: /s/ Francois Michelon |
Name: Brian McEathron | Name: Francois Michelon |
Title: GM General Imaging Ultrasound | Title: CEO |
Date: January 30, 2018 | Date: January 6, 2018 |